Ignite Creation Date:
2024-05-06 @ 1:41 PM
Last Modification Date:
2024-10-26 @ 1:18 PM
Study NCT ID:
NCT04094402
Status:
UNKNOWN
Last Update Posted:
2019-09-23
First Post:
2019-09-16
Brief Title:
Epi-GERD Study Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease GERD
Sponsor:
Scandinavia Pharma
Organization:
Scandinavia Pharma
Study Overview
Official Title:
Epi-GERD Study Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux
Status:
UNKNOWN
Status Verified Date:
2019-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Epi-ERGE
Brief Summary:
Cross-sectional epidemiological study in patients with diagnosis of GERD Gastroesophageal Reflux Disease and with current treatment or with a history of recent treatment with some PPI Proton Pump Inhibitor in order to evaluate the persistence and or relapse of symptoms of GERD
Detailed Description:
OBJECTIVE To carry out an evaluation about the persistence and or relapse of symptoms in Colombian patients with diagnosis of GERD
MATERIALS AND METHODS A multicentric cross-sectional epidemiological study will be carried out in Colombian patients with diagnosis of GERD and with current treatment or with a history of recent treatment with some PPI Proton Pump Inhibitor The persistence and or relapse of symptoms will be evaluated as the main variable The secondary variables to be evaluated include Demographical analysis treatment s used by patients adverse events associated with the treatments comorbidities and risk factors The analysis will be carried out from two perspectives A first descriptive approach and a second analytical approach with a level of significance of 5
MATERIALS AND METHODS A multicentric cross-sectional epidemiological study will be carried out in Colombian patients with diagnosis of GERD and with current treatment or with a history of recent treatment with some PPI Proton Pump Inhibitor The persistence and or relapse of symptoms will be evaluated as the main variable The secondary variables to be evaluated include Demographical analysis treatment s used by patients adverse events associated with the treatments comorbidities and risk factors The analysis will be carried out from two perspectives A first descriptive approach and a second analytical approach with a level of significance of 5
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None